Skip to main content
See every side of every news story
Published • loading... • Updated

Aptar Pharma Expands Services Capabilities to Support Development of Inhaled and Nasal Drug Products Containing Controlled Substances

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Pharma's Boonton, NJ site received DEA Schedule II-III registration, expanding integrated development and clinical supply services for OINDPs.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

HealthTech HotSpot broke the news on Friday, November 13, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal